International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series: World’s leading Event Organizer


Recommended Conferences for Under Venom Immunotherapy

Under Venom Immunotherapy

As per available reports about 2 relevant journals, 1 Conferences, 1 workshops are presently dedicated exclusively to under venom immunotherapy and about 2,070 articles are being published on under venom immunotherapy. 

Under venom immunotherapy:

1. Insect venom immunotherapy (VIT) is the injection, under the skin, of gradually incrementing doses of insect venom. VIT commences with a minutely minuscular dose that is gradually incremented. This process causes a transmutation in how the immune system responds to the venom.
2. There is a high caliber of scientific evidence to show that VIT obviates rigorous allergic reactions (anaphylaxis) to insect stings, with the aim of obviating morbidity and death. More than 30 years experience has perceived it to be efficacious, well abode, safe when administered in opportune settings and associated with an amelioration in quality of life for patients.
3. Different insect venoms are associated with different risks of allergic reaction to the VIT injections themselves. In this regard, Jack Jumper Ant (JJA) VIT appears to be kindred to honeybee VIT.
4. Any clinical accommodation that is competent to distribute honeybee VIT is additionally competent to distribute JJA VIT. The same protocols used to administer honeybee VIT can be applied to JJA VIT.
5. The protocols of administration associated with the lowest risks of allergic reactions to VIT are the more gradual outpatient ("conventional" and "semirush") approaches.
6. Expedited inpatient approaches ("rush" and "ultrarush") may be utilized, but these present higher risks of allergic reactions. Patients offered expedited inpatient treatment should be conscientiously culled so as to omit those at greatest risk of decompensating during a reaction.
7. There is a jeopardy of allergic reactions to VIT injections. Emergency procedures and experience with treating anaphylaxis must be in place for the treatment of these reactions. This applies to all forms of injection immunotherapy, not just JJA VIT.
8. JJA VIT is unique because the JJA is found only in Australia. The number of patients affected on a worldwide substratum is therefore minute. This presents a quandary for the manufacture and supply of venom extract because there is no “economy of scale”.
9. At present, JJA venom is only available as an Active Pharmaceutical Ingredient (API), i.e. in concentrated form. This restricts its use to allergy accommodations that are able to manage formulation, storage and dispensing on-site.
10. Where there are constrained resources for providing JJA VIT, allergy accommodations should prioritise available treatment places for patients that (i) have had documented hypotensive or hypoxaemic reactions requiring emergency medical treatment, and (ii) have an perpetual risk of fortuitous stings.

Hymenoptera venom allergy is an immunoglobulin E (IgE)- mediated hypersensitivity to the venom of insects in the insect order Hymenoptera. This allergic reaction may be caused by stings from a number of species in this insect order, occurring only in epersons who have previously been sensitized to Hymenoptera venom

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide. 

Global allergy diagnostic and treatment of undervenom immunotherapy market is projected to increase to nearly $35.3 billion by 2015 from $31.5 billion in 2014. This market is expected to reach $46.8 billion by 2020, corresponding to a compound annual growth rate (CAGR) of 5.8% during 2015 to 2020 period.


Conferences :

Socities :

• Vaccination Clinics - Humane Society of Broward County
• Vaccine Clinics - Connecticut Humane Society
• Vaccine Clinics | Wisconsin Humane Society
• Australian Vaccinologists society
• The american Vaccines and vaccination society.
• US Immunology society.
• World immunization Association
• American Immunologists association.
• North California medical society

Companies :

• RMS MS Contin
• Endo Pharmaceuticals
• Carbex.
• Benforce M
• Minitide
• Reglide
• Rezult.
• Zolmelis
• Jalra
• Chromet

This page will be updated regularly.

This page was last updated on 15th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
[email protected]
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
[email protected]
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
[email protected]
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
[email protected]
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
[email protected]
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
[email protected]
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
[email protected]
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
[email protected]
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
[email protected]
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
[email protected]
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
[email protected]
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
[email protected]
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
[email protected]
+1-702-508-5200 Ext:8051

Program Enquiries
Media Partners | Advertising